{"id":22021,"title":"Five things you need to know about PD-1 inhibitor","title_html":"Five things you need to know about PD-1 inhibitor","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.zrdf526","doi_status":2,"uri":"five-things-you-need-to-know-about-pd-1-inhibitor-zrdf526","type_id":1,"published_on":1554276936,"version_id":0,"created_on":1554263520,"categories":null,"creator":{"name":"Alex Brown","affiliation":null,"username":"alex-brown1","link":"https:\/\/medium.com\/@yx2017be\/five-things-you-need-to-know-about-pd-1-inhibitor-e17ff7ff53e1","image":{"source":"\/img\/avatars\/010.png","placeholder":"\/img\/avatars\/010.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"research_interests":null},"journal":null,"journal_name":null,"journal_link":null,"public":1,"has_versions":0,"link":"https:\/\/medium.com\/@yx2017be\/five-things-you-need-to-know-about-pd-1-inhibitor-e17ff7ff53e1","total_collections":0,"number_of_steps":0,"authors":[{"name":"Alex Brown","affiliation":"BOC Sciences","username":"alex-brown1","link":null,"image":{"source":"\/img\/avatars\/010.png","placeholder":"\/img\/avatars\/010.png"},"badges":[],"research_interests":null}],"versions":[],"groups":[],"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"steps":[],"materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\"><a style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">PD-1 inhibitors<\/span><\/a><span>, including PD-1 antibodies and PD-L1 antibodies, are a new drug for tumor immunotherapy. Unlike surgery, chemoradiotherapy, and targeted drugs, the PD-1 inhibitor itself does not directly kill cancer cells, but rather activates the patient's own immune system to fight cancer.<\/span><\/div><div class = \"text-block\"><span>The first clinical trial of PD-1 inhibitor began in 2006 and it was first officially marketed in September 2014. Since then, it has been selected by <\/span><span style = \"font-style:italic;\">Scienc<\/span><span>e and the American Society of Clinical Oncology as the \u201cBiggest Progress of the Year\u201d. The inventor of PD-1 inhibitors has also won the Lasker Award, which is known as the \"Nobel Prize in Medicine\". <\/span><\/div><\/div>","changed_on":1554276936}